Introduction
Non-alcoholic fatty liver disease (NAFLD) is a multifaceted condition that includes pathological manifestations ranging from the accumulation of neutral lipids in the cytoplasm of hepatocytes (steatosis) to the combination of steatosis with inflammation, a stage known as nonalcoholic steatohepatitis (NASH) (Sanyal, 2005) . NASH is the aggressive form of NAFLD and increases the risk for advanced liver disease culminating in hepatic fibrosis, cirrhosis and hepatocarcinoma (Sanyal, 2005) . The mechanisms underlying the progression of NASH have not been completely elucidated, but repeated insults to the liver of these patients lead to inflammatory injury, hepatocyte death and the expansion of extracellular matrix (fibrosis) (Friedman, 2004) . Therefore, pharmacological interventions that protect liver cells from inflammatory injury and fibrosis could be useful as a therapy for NASH.
Cyclic nucleotides, such as cGMP, play a major role in cell signalling and tissue homeostasis. Pharmacological modulation of the cGMP pathway is a potential target for therapy in complex diseases Buglioni and Burnet, 2016) . Indeed, small molecules with the ability to activate/stimulate soluble guanylate cyclase (sGC), which produces the second messenger cGMP in response to NO binding, have been reported to be therapeutically efficacious in several conditions, including pulmonary hypertension and chronic thromboembolic pulmonary hypertension (Ghofrani et al., 2013a,b) . In preclinical models, drugs modulating the NO-sGC-cGMP pathway have demonstrated potential therapeutic roles in hypertension, atherosclerosis, restenosis and thrombosis (Tulis et al., 2000; Stasch et al., 2002) . Also, at the preclinical level, these molecules have been shown to have important reno-protective and cardiacprotective actions, ameliorating renal and cardiac fibrosis (Hohenstein et al., 2005; Patrucco et al., 2014; Stasch et al., 2015) . Molecules with the ability to impact the NO-sGC-cGMP pathway block inflammatory responses and the conversion of human lung fibroblasts into myofibroblasts (Ahluwalia et al., 2004; Pan et al., 2005; Dunkern et al., 2007) . Therefore, pharmacological interventions that affect the NO-sGC-cGMP pathway are good candidates for decreasing inflammation and fibrosis in patients with NASH.
Alterations in the NO-sGC-cGMP pathway resulting in increased tissue cGMP concentrations can be induced by four different interventions, namely, through the use of (i) specific PDE5 and PDE9 inhibitors, (ii) NO donors, (iii) sGC activators and (iv) sGC stimulators Buglioni and Burnet, 2016) . PDE5 inhibitors, which prevent cGMP hydrolysis, were unable to enhance the exercise capacity of patients with heart failure (Redfield et al., 2013) , and NO donors depend on a patient's biometabolism to be activated (Buglioni and Burnet, 2016) . In contrast, direct sGC stimulators and activators provide a feasible alternative for the pharmacological manipulation of the NO-sGC-cGMP pathway. Activators of sGC are NO-and haem-independent agonists that act only when the haem group of sGC is oxidized or when sGC is in a haem-free state. In contrast, stimulators of sGC act directly on the reduced form of this enzyme in a haem-dependent manner, increasing its sensitivity to NO and thereby amplifying the effects of NO (Buglioni and Burnet, 2016) . These characteristics allow sGC stimulators to increase cGMP signalling even when the endogenous NO/cGMP pathway is impaired (Stasch and Hobbs, 2009) . In this study, we explored the effects of the sGC stimulator IW-1973 which is under clinical investigation for the treatment of heart failure with preserved ejection fraction but with the added complications of diabetes. IW-1973 was selected because of its extensive tissue distribution, high oral bioavailability and long pharmacokinetic half-life, which is consistent with once daily dosing in humans (Hanrahan et al., 2017) . Specifically, in this study, we explored the effects of IW-1973 in an optimized murine model of NASH induced by the combination of a choline-deficient L-amino acid-defined diet with a high-fat (CDAAH) diet (Matsumoto et al., 2013) . This NASH model is useful for gaining further insights into human liver disease and for the development of effective therapies because it induces hepatic inflammation that rapidly progresses to liver fibrosis. In addition, since adiposity plays a major role in NASH progression (Shoelson et al., 2007) , we also explored the effects of IW-1973 in the classic, long-term model of dietary obesity induced by feeding a high-fat diet (HFD).
Methods

Animals and experimental design
Male C57BL/6J mice (Charles River Laboratories, SaintAubin-lès-Elbeuf, France) were housed on woodchip bedding in cages with 50-60% humidity and a 12 h light/dark cycle and given free access to food and water. At 6 weeks of age (18-22 g), mice were randomly assigned to four independent groups, which received the following diets for 9 weeks: group 1 were fed a standard pellet chow diet (D12450J; 10% kcal from fat) (n = 10); group 2 were fed the CDAAH diet (A06071302; 60% kcal from fat) (n = 15), as described by Matsumoto et al. (2013) ; group 3 were fed the CDAAH supplemented with the sGC stimulator IW-1973 (1 mg·kg À1 ·day À1 ) (n = 10); and group 4 were fed the CDAAH plus IW-1973 (3 mg·kg À1 ·day À1 ) (n = 10). Diets were prepared by Research Diets (New Brunswick, NJ, USA). Additional groups of mice were fed the standard pelleted chow (n = 5), a HFD (D12492i; 60% kcal from fat) (n = 10), a HFD supplemented with IW-1973 (1 mg·kg À1 ·day À1 ) (n = 10) or a HFD plus IW-1973 (3 mg·kg À1 ·day À1 ) (n = 10) for 16 weeks. At the end of the intervention period, mice were killed by an overdose of anaesthetic (a mixture of 0.1 mg ketamine . g -1 body wt and 0.01 mg xylazine . g -1 body wt). Blood was collected, and plasma was obtained by centrifugation at 800× g for 10 min. Liver, epididymal white adipose tissue (WAT) and scapular brown adipose tissue (BAT) were excised and rinsed in Dulbecco's PBS with calcium and magnesium (DPBS ++ ).
Portions of liver and WAT were fixed in 10% formalin and embedded in paraffin. Other portions of liver were placed in OCT immersed in cold 2-methylbutane on dry ice and kept at À80°C. Portions of liver, WAT and BAT were also snap frozen in liquid nitrogen for further analysis. The administration of the experimental diets had no major impact on animal welfare, apart from a slight decrease in body weight in animals receiving the CDAAH diet. All studies were conducted in accordance with the criteria of the Investigation BJP R Flores-Costa et al.
and Ethics Committee of the Hospital Clínic and the European Community laws governing the use of experimental animals. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Biochemical analyses
Plasma concentrations of glucose, total cholesterol, triglycerides (TAGs), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined by standard laboratory procedures.
Tissue TAG and cholesterol levels
Liver tissue was homogenized in NP40 Substitute Assay Reagent (Cayman Chemicals, Ann Arbor, MI, USA) containing protease inhibitors (Complete Mini; Roche Diagnostics, Basel, Switzerland). Homogenates were centrifuged 10 min at 10 000× g at 4°C, and supernatants were diluted 1:2-1:10 or 1:100-1:400 in assay buffer for TAG and cholesterol measurements respectively. Samples were assayed using triglyceride colorimetric (reference 10010303; Cayman Chemicals) or cholesterol fluorimetric (reference 10007640; Cayman Chemicals) assay kits.
Histological analysis of liver steatosis
Hepatic steatosis was assessed by Oil Red O staining of OCTembedded cryosections. Briefly, liver sections were fixed in 60% isopropanol for 10 min and stained with 0.3% Oil Red O in 60% isopropanol for 30 min and subsequently washed with 60% isopropanol. Sections were counterstained with Gill's haematoxylin, washed with 4% acetic acid solution and mounted with aqueous solution. Sections were visualized at 200× magnification in a Nikon Eclipse E600 microscope (Nikon, Kawasaki, Japan). Relative areas of steatosis, expressed as % of Oil Red O staining, were quantified by histomorphometry using a computerized image analysis system (Cell^D; analySIS imaging processing, Münster, Germany). A minimum of 10 independent fields per sample were evaluated.
Histological analysis of inflammation and fibrosis
Liver and WAT samples were fixed in 10% formalin, embedded in paraffin, cut into 5 μm sections and stained with haematoxylin-eosin (H&E) at the Pathology Department of the Hospital Clínic. Liver necroinflammatory injury at 200× magnification was analysed blinded, and the NAFLD activity score (NAS) was calculated by a registered pathologist unaware of the treatments (A. D.). The NAS grading system was described by Liang et al. (2014) as a simple NAFLD scoring system with high reproducibility that is applicable for different rodent models and for all stages of NAFLD aetiology. NAS is calculated as the unweighted sum of the scores for steatosis (including macro-vesicular and micro-vesicular steatosis separately and by hepatocellular hypertrophy) and inflammation (scored by analysing the amount of inflammatory foci/field). Liver and WAT sections were also stained with Sirius Red. Briefly, sections were incubated for 10 min in 0.5% thiosemicarbazide and stained in 0.1% Sirius Red F3B in saturated picric acid for 1 h, followed by a wash with a 0.5% acetic acid solution. 
Isolation of hepatocytes, hepatic stellate cells and Kupffer cells
Hepatocytes and non-parenchymal liver cells were isolated from C57BL/6J mice by a three-step in situ perfusion procedure using 0.04% collagenase IV through the portal vein, as previously described by López-Vicario et al. (2015) and Morán-Salvador et al. (2013) . 
Differentiation and incubation of 3T3-L1 adipocytes
Analysis of GUCY1A2 by endpoint RT-PCR
Endpoint amplification of GUCY1A2 and GAPDH was performed with the following specific oligonucleotides: GUCY1A2, sense 5 0 -GAAGTCATCCTCGGCGTATC-3 0 and antisense 5 0 -ACCCAGCTTTTTGTTTTTAGTTGA-3 0 ; GAPDH, sense 5 0 -TCCAGTATGACTCCACTC-3 0 and antisense 5 0 -ATTTCTCGTGGTTCACAC-3 0 . The specificity of primers was confirmed in the GenBank database using the basic local alignment search tool. PCR products were analysed by electrophoresis in 2.0% agarose gels and visualized by SYBR safe staining, using a 100 bp DNA ladder (Invitrogen, Carlsbad, CA, USA). 
Analysis of protein expression by Western blot
Analysis of cytokine levels
TNF-α and MCP-1 levels in liver tissue were assessed in a Luminex 100 system (Luminex Corp., Austin, TX, USA) using a custom-made MILLIPLEX MAP Mouse High Sensitivity T Cell Magnetic Bead Panel (Merck Millipore, Billerica, MA, USA). Briefly, 25 μL of diluent and 25 μL of liver protein extract were added to each well before the addition of premixed microbeads (25 μL). The plate was incubated overnight at 4°C with shaking, then washed and reincubated with 25 μL of detection antibody for 1 h. The plate was washed again and incubated with 25 μL of streptavidin-phycoerythrin for 30 min. The plate was finally washed twice, and the beads were resuspended with 150 μL of sheath fluid and analysed in the Luminex 100 system. Readouts were detected as mean fluorescence intensity by the instrument, and values were subsequently converted to pg·mL À1 by extrapolation from a set of standards that were run simultaneously in the assay.
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized, rehydrated and pretreated with sodium citrate (0.05%) to unmask the antigen, followed by incubation with H 2 O 2 (0.3%) for 25 min at room temperature in dark conditions, to block endogenous peroxidase activity, and with 2% BSA for 20 min at room temperature, to avoid nonspecific binding of the primary antibody. Thereafter, the liver sections were incubated 1 h at room temperature with a primary rat antimouse F4/80 antibody (dilution 1:100; Bio-Rad, Hercules, CA, USA) followed by incubation for 15 min at room temperature with a biotinylated rabbit anti-rat IgG secondary antibody ( Tissue levels of cAMP and cGMP
Liver tissue was homogenized in 5 vol of 5% trichloroacetic acid (TCA) in order to purify tissue samples from PDEs. Homogenates were centrifuged 10 min at 1500× g at 4°C, and TCA was extracted three times from supernatants using 5 vol of water-saturated diethyl ether. Extracted samples were heated at 70°C for 5 min to remove residual ether from aqueous layer and stored at 4°C for determination of cAMP and cGMP levels. Standard curves were prepared with the matrix solution of 5% TCA water-saturated diethyl ether, and standards and samples were acetylated prior to the analysis in competitive enzyme immunoassays (cAMP: reference 581001 and cGMP: reference 581021; Cayman Chemicals).
Liver and plasma levels of IW-1973
Liver tissue, plasma samples and standards were analysed using a Thermo Vantage Triple Quadrapole LC/MS-MS (Thermo Fisher Scientific, Waltham, MA, USA) in positive ion-mode electrospray ionization, linked to an Aquity UPLC (Waters, Milford, MA, USA). Liver tissues were weighed and diluted 30× with 10% acetic acid in 90% water and homogenized using an Omni Prep homogenizer (Omni International, Kennesaw, GA, USA). Liver tissue proteins and plasma samples were precipitated using 50% acetonitrile and 50% methanol containing 20 ng·mL À1 internal standard. The samples were centrifuged at 2670× g at 4°C for 30 min. The supernatant was transferred and dried under nitrogen at 55°C and resuspended in the starting mobile phase. A standard curve from 1-1000 ng·mL À1 was prepared in 30× diluted liver tissue and also in plasma. The samples were loaded onto a Thermo Hypersil Gold 2.1 × 50 mm, 5 μm particle-size column with a javelin guard (Hypersil Gold 5 μm 10 × 2.1 mm). The mobile phase consisted of aqueous 0.1% formic acid (mobile phase A) and acetonitrile with 0.1% formic acid (mobile phase B). The flow rate was 0.4 mL·min À1 . The gradient holds at 80% mobile phase A for 0.5 min, ramps to 5% mobile phase A by 2.5 min and holds for 0.5 min before returning to 80% mobile phase A by 4 min. The total run time was 4 min per sample. 
Data and statistical analysis
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c,d) .
Results
We first assessed the status of the NO-sGC-cGMP pathway in CDAAH mice. A schematic diagram of the NO-sGC-cGMP signalling pathway is shown in Figure 1A . As shown in Figure 1B , the gene encoding the key enzyme of this pathway (the sGC GUCY1A2) is constitutively expressed in liver tissue and quiescent hepatic stellate cells (HSC) but not in hepatocytes. GUCY1A2 expression was not detected in activated HSC and Kupffer cells by endpoint PCR. Consistent with impairment of the NO-sGC-cGMP pathway in liver disease, CDAAH mice showed a reduced expression of the genes encoding GUCY1A2 and NOS3 and lower tissue levels of cGMP than chow-fed control mice ( Figure 1C -E). CDAAH mice also displayed reduced mRNA expression of the cGMP-metabolizing enzymes (i.e. PDE5A and PDE9A) ( Figure 1F , G), whereas the expression of PKG1 and PKG2 ( Figure 1H, I ) and the downstream effector VASP (Supporting Information Figure S1A ) was not different between CDAAH mice and controls. CDAAH mice had higher hepatic levels of cAMP compared with chow-fed controls (Supporting Information Figure S1B ). Administration of IW-1973 to CDAAH mice increased GUCY1A2 and NOS3 expression to similar levels to controls while significantly raising cGMP concentrations in the livers of these animals ( Figure 1C-E) . Of interest, IW-1973-treated mice had a lower expression of cGMP-metabolizing enzymes ( Figure 1F, G) . In addition, IW-1973-treated mice showed significantly lower mRNA expression of PKG2 ( Figure 1I ), a finding that was confirmed at the protein level by Western blot analysis ( Figure 1J ). There were no significant differences in hepatic PKG1 expression ( Figure 1H , J) and cAMP levels (Supporting Information Figure S1B ) between IW-1973-treated and CDAAH mice. Circulating plasma levels of IW-1973, as determined by LC-MS/MS, were 11.3 ± 3.7 nM in the group of mice receiving IW-1973 at a dose of 1 mg·kg À1 ·day
À1
and 30.4 ± 13.8 nM for those receiving IW-1973 at a dose of 3 mg·kg À1 ·day À1 . The 1 and 3 mg·kg À1 ·day À1 doses were selected to achieve plasma levels that have no effect on BP in normal mice, and the observed plasma levels of IW-1973 have no effect on BP in normal mice where plasma levels of approximately 200 nM are required to produce a 4.5 mmHg drop in mean arterial BP measured by telemetry (data not shown). IW-1973 concentrations in CDAAH mouse livers were significantly higher than in plasma, with levels of 457.4 ± 98.6 and 971.4 ± 190.7 nM for the 1 and 3 mg·kg À1 · day À1 respectively.
Compared with chow-fed mice, CDAAH-fed mice had significantly lower body weights (Figure 2A ), significantly higher liver-to-body weight ratios ( Figure 2B ) and lower BAT-to-body weight ratios (Supporting Information Figure S2A ). No changes in WAT weight were observed ( Figure 2C ). CDAAH mice showed reduced plasma levels of glucose, total cholesterol and TAG (Supporting Information Figure S2B ). Moreover, CDAAH mice exhibited exacerbated hepatic steatosis revealed by extensive Oil Red O staining of neutral lipids (Supporting Information Figure S2C ) and hepatic TAG accumulation (Supporting Information Figure S2D ). In agreement with enhanced steatosis, CDAAH mice showed down-regulated expression of the lipolytic PPARα gene accompanied by a marked up-regulation of FAT/CD36, a gene involved in hepatic fatty acid uptake (Supporting Information Figure S2E ). No changes in hepatic cholesterol levels were observed (Supporting Information Figure S2F) . Administration of the sGC stimulator IW-1973 did not alter body weight (Figure 2A ) but significantly reduced liver-and WAT-to-body weight ratios ( Figure 2B, C) . IW-1973 also reduced BAT-to-body weight ratio (Supporting Information Figure S2A ). A modest reduction in plasma glucose levels (Supporting Information Figure S2B ) and Oil Red O staining (Supporting Information Figure S2C ) was observed in mice receiving IW-1973 . No effects on plasma and hepatic TAG and cholesterol levels were observed (Supporting Information Figure S2B , D, F), whereas PPARα and FAT/CD36 expression was slightly modified after IW-1973 treatment (Supporting Information Figure S2E ). Consistent with the fact that CDAAH is an established model of inflammatory liver injury, CDAAH mice showed marked hepatic inflammation as compared with controls, as revealed by histological analysis of H&E-stained liver sections ( Figure 2D ). CDAAH mice also showed increased plasma AST and ALT levels ( Figure 2E ). Consistently, CDAAH mice had a higher NAS compared with controls ( Figure 2F ). CDAAH mice also showed increased area of positive immunostaining for the specific macrophage marker F4/80, indicating greater macrophage infiltration ( Figure 2G ). Moreover, confirming these histological and immunohistochemical results, CDAAH mice had higher mRNA expression of TNF-α and MCP-1 in comparison with chow-fed control mice (Figure 2  H) . Increased expression of these inflammatory genes was confirmed at the protein level ( Figure 2I ). Up-regulation of IL-6, IL-10 and IL-1ra was also seen in CDAAH mice (Supporting Information Figure S3 ). Addition of the sGC stimulator IW-1973 to CDAAH diet was associated with significantly lower hepatic inflammation and plasma ALT levels, reduced NAS and macrophage infiltration and decreased tissue levels of TNF-α and MCP-1 (Figure 2D-I) . Reduced IL-6 and IL-1ra expression was also seen in IW-1973-treated mice (Supporting Information Figure S3) .
Consistent with the fact that CDAAH is an established model of inflammatory liver injury that rapidly progresses to liver fibrosis, CDAAH mice exhibited increased Masson's trichrome and Sirius Red staining as well as α-SMA immunostaining indicative of extensive liver fibrosis ( Figure 3A, B) . Furthermore, the expression of fibrogenic genes, including COL1A1, COL1A2, MMP2, TGF-β1 and TIMP-1, was significantly up-regulated in CDAAH mice ( Figure 3C ). In CDAAH mice receiving IW-1973, the areas stained with Masson's trichrome, Sirius Red and α-SMA were significantly smaller compared with CDAAH-fed mice ( Figure 3A, B) . In addition, the expression of all fibrogenic genes was down-regulated in mice receiving IW-1973 ( Figure 3C ).
We next explored the effects of IW-1973 in the classic, long-term model of obesity-induced NASH induced by a HFD, which primarily is an established model of hepatic steatosis. As expected, HFD-induced obese mice exhibited widespread Oil Red O staining, increased hepatic TAG levels and up-regulated expression of the lipogenic regulator SREBP-1c and the fatty acid oxidation regulator PPARα ( Figure 4A-E) . These mice exhibited very mild fibrosis ( Figure 4A, B) . The addition of the sGC stimulator IW-1973 produced a significant reduction in hepatic steatosis, hepatic TAG levels and lipogenic gene expression and augmented gene expression of fatty acid oxidation regulators (Figure 4 A-E). In contrast, IW-1973 modestly attenuated Sirius Red and α-SMA staining ( Figure 4A, B) . Significant reductions in plasma AST levels were observed in mice receiving IW-1973 (Supporting Information Figure S4 ).
WAT plays a crucial role in the development of obesityinduced NASH (Shoelson et al., 2007) . Therefore, we characterized the NO-sGC-cGMP pathway in this insulin-sensitive tissue, in HFD-induced obese mice. These mice gained more body weight and had higher WAT-and BAT-to-body weight ratios compared with controls ( Figure 5A , B). As compared with lean chow-fed control mice, HFD-induced obese WAT also showed a greater number of crown-like structures indicating enhanced macrophage infiltration ( Figure 5C ). Augmented infiltration of macrophages into WAT from HFD-induced obese mice was confirmed by morphometric analysis of F4/80 immunostaining ( Figure 5D ). Of interest, morphometric analysis of H&E-stained WAT sections revealed increased adipocyte area in obese mice ( Figure 5C , E). These WAT phenotypic changes in obese mice were associated with significant down-regulation of NOS3, GUCY1A2, PKG1, PKG2 and PDE5A (Supporting Information Figure  S5A -E). VASP expression was not different between the two groups (Supporting Information Figure S5F ). Increased tissue remodelling and fibrosis was also a hallmark of obese WAT, as revealed by enhanced Sirius Red staining and TIMP-1 overexpression (Supporting Information Figure S5G , H). Of note, TIMP-1 expression was inversely correlated with the expression of the cGMP-synthesizing enzyme sGC α subunit gene GUCY1A2 (Supporting Information Figure S5I ). In HFD fed mice also treated with the sGC stimulator IW-1973, the body weight or WAT-and BAT-to-body weight ratios were not altered compared with controls ( Figure 5A, B) . However, HFD mice treated with IW-1973 had fewer crown-like structures and a lower degree of macrophage infiltration compared with HFD mice receiving placebo ( Figure 5C, D) . Of interest, WAT from HFD-induced obese mice treated with IW-1973 contained adipocytes of reduced size as compared with WAT from placebo-treated animals ( Figure 5E ). Smaller adipocyte area was not secondary to greater lipolysis and release of free fatty acids to the circulation, since phosphorylation of the master lipolytic enzyme HSL was not significantly modified by IW-1973 ( Figure 5F ). However, IW-1973 induced an increase in the autophagy flux in WAT, as a higher LC3II/LC3I ratio in conjunction with a lower p62 protein expression was observed in the groups of HFD obese mice receiving IW-1973 ( Figure 5G ). Increased autophagy was confirmed in 3T3-L1 adipocytes incubated with increasing concentrations of IW-1973 ( Figure 5H ). Finally, sGC stimulation did not translate into increased WAT thermogenesis, since UCP1, CIDEA, PGC-1α and PRDM16 expression remained unchanged after IW-1973 treatment (Supporting Information- Figure S6A ). Similar effects were observed in BAT (Supporting Information Figure S6B ).
Discussion
Our study provides novel insights into the role of the NO-sGC-cGMP pathway in liver disease. In particular, our study provides evidence at the experimental level that sGC stimulation prevents hepatic steatosis, inflammation and fibrosis, which are the three key features of NASH. One of the major novelties of our study is that it demonstrates for the first time the hepatoprotective actions of a sGC stimulator in two distinct and independent experimental models of NASH. These two models cover the spectrum of liver abnormalities observed in NASH ranging from hepatic steatosis (HFD model) to inflammation progressing to fibrosis (CDAAH model). In the HFD model, a murine model of hepatic steatosis secondary to obesity, the sGC stimulator IW-1973 had a profound anti-steatotic effect and a moderate anti-fibrotic action in the liver accompanied by the promotion of the healthy expansion of adipocytes in the WAT. In the CDAAH model, a murine model of hepatic inflammation and fibrosis, the sGC stimulator IW-1973 ameliorated hepatic inflammation and exerted a remarkable protection against liver fibrosis in the context of a mild anti-steatotic action.
As far as we know, the present report is the first study assessing the pharmacological modulation of sGC in the CDAAH model of NASH. The CDAAH is a new model that optimizes the original MCD model, which main drawback is the drastic loss of weight in the animals. In the CDAAH model, this disadvantage is superseded by combining the MCD and HFD models, resulting in a stabilization of the weight loss (Liang et al., 2014) . Our data in these mice demonstrated that administration of IW-1973 restored hepatic GUCY1A2 and NOS3 expression levels and down-regulated PDE5 and PDE9, leading to the augmentation of hepatic cGMP levels. Augmented cGMP levels in response to IW-1973 treatment correlated well with direct improvements in hepatic inflammation, resulting in reduced macrophage infiltration, hepatocyte ballooning and the mRNA and protein levels of TNF-α and MCP-1. These findings are in agreement with the results communicated by Ahluwalia et al. (2004) , which demonstrated that sGC stimulators inhibit IL-1β-induced leukocyte rolling and adhesion, secondary to the modulation of adhesion molecules such as L-selectin and P-selectin. Furthermore, genetic ablation of cGMP-dependent PKG1 or VASP causes liver and WAT inflammation (Handa et al., 2011; Lutz et al., 2011) . The most important finding of our study was the remarkable anti-fibrotic effect exerted by the sGC stimulator IW-1973 in the liver of CDAAH mice. Indeed, histopathological analysis of liver sections of mice receiving IW-1973 revealed decreased Masson's trichrome and Sirius Red staining and α-SMA immunostaining. Moreover, IW-1973 exerted significantly down-regulated a battery of genes involved in the fibrogenic/remodelling process such as COL1A1, COL1A2, MMP-2, TGF-β1 and TIMP-1. IW-1973 is a sGC stimulator with a large volume of distribution in the rat and particularly high levels in the liver (approximately 40-fold higher levels compared with plasma). The increased liver distribution probably contributes to the antifibrotic effects observed with IW-1973, which were achieved at doses that correspond to plasma concentrations that have no effect on systemic BP in normal mice. Our findings agree with previous publications demonstrating anti-remodelling effects of agents modulating the cGMP pathway in in vivo and in vitro models of renal, cardiac, dermal and pulmonary fibrosis (Hohenstein et al., 2005; Dunkern et al., 2007; Cui et al., 2014; Patrucco et al., 2014; Beyer et al., 2015; Wang et al., 2016) . Moreover, our findings are consistent with previous publications reporting the antifibrotic actions of NO donors or sGC activators in vitro in renal myofibroblasts (Wang et al., 2016) and in vivo in models of biliary and toxic (i.e. carbon tetrachloride and thioacetamide) liver injury (Moal et al., 2006; Knorr et al., 2008; Xie et al., 2012) . The mechanism underlying the antifibrotic actions of agents working on the cGMP pathway is still unclear, but IW-1973 is probably targeting hepatic stellate cells, the main fibrogenic cell type in the liver. In this regard, Hall et al. (2017) have recently confirmed earlier work showing that hepatic GUCY1 is mainly expressed in hepatic stellate cells but not in hepatocytes. These authors have also shown that hepatic stellate cells and not hepatocytes respond to sGC stimulation by IW-1973 (Hall et al., 2017 . In this study, Hall et al. (2017) have also provided evidence that IW-1973 is able to block TGF-β-induced α-SMA protein levels -1973 (1, 3 and 10 μM) . Results are expressed as mean ± SEM. *P < 0.05 for HFD versus CHOW. Blot data subjected to statistical analysis were from n = 5 experiments. Scale bar = 50 μm.
in hepatic stellate cells. These findings are consistent with our results showing a significant and dose-dependent downregulation of TGF-β1 in CDAAH mice receiving IW-1973, as well as with previous studies indicating that the blockage of the non-canonical TGF-β pathway by increased cGMP may be responsible for the anti-fibrotic effects (Cui et al., 2014 , Beyer et al., 2015 . Another major finding of our study was that the administration of the sGC stimulator IW-1973 blunted hepatic steatosis in the HFD-induced obesity model. Although the mechanisms underlying this effect are not defined, Ayala et al. (2007) reported that chronic treatment with sildenafil, a selective PDE5 inhibitor, was accompanied by an improvement in energy balance and insulin sensitivity in HFD-fed mice. In line with the anti-steatotic actions seen in our study, cardiomyocytes overexpressing a constitutively active sGC showed better fatty acid trafficking and reduced TAG accumulation (Khairallah et al., 2008 ). An interesting feature of the HFD model is that it provides the optimal setting to investigate the influence of extrahepatic factors, mainly those derived from WAT, on the progression of hepatic steatosis (Heydemann, 2016) . Indeed, our study demonstrated that the beneficial effects of the sGC stimulator IW-1973 were not only limited to the liver but also extended into the WAT depot. WAT plays a critical role in regulating energy homeostasis, and its functional integrity is required for the balanced body metabolism of a healthy organism (Trayhurn, 2005; Shoelson et al., 2007) . In obese conditions, the presence of a chronic 'low-grade' state of inflammation in WAT leads to altered WAT endocrine and metabolic functions (Ferrante, 2007, Elks and . As a consequence of this dysregulation, there is an unbalanced production of proinflammatory adipokines accompanied by an impairment in WAT lipolysis, which results in an overspill of free fatty acids into the liver (Ouchi et al., 2011) . Therefore, in recent years, WAT has emerged as a target for the prevention of NASH. The results of the current study demonstrate a significant reduction in macrophage infiltration in response to the administration of the sGC stimulator IW-1973, thus suggesting that an amelioration of WAT inflammation contributed to the protective actions of this drug on the liver. This finding is consistent with those from a recent study by Sanyal et al. (2017) exploring the mechanisms underlying the antiinflammatory effects of sGC stimulators in WAT. These authors performed a comprehensive dissection of the cGMP signalling pathway in this tissue and demonstrated that the intensity of obesity-induced inflammation correlates well with the amplitude of cGMP dysregulation, through pathways such as TNF-α-mediated suppression of sGC and NF-κB or PKG suppression by JNK signalling (Sanyal et al., 2017) .
Another interesting finding of our study was that IW-1973 treatment was associated with a dose-dependent reduction in adipocyte area, a finding similar to that reported by Mitschke et al. (2013) in primary murine adipocytes using 8-pCPT-cGMP, an analogue of the natural signal molecule cGMP. Along these lines, Hoffmann et al. (2015) also reported a reduction in the size of human adipocytes in response to BAY 41-8543, a small molecule stimulator of sGC. Overall, these findings are in agreement with the hypothesis by Sun et al. (2011) , who suggested that a decrease in adipocyte size is a parameter for healthy expansion of WAT. Since in our study the reduction in the size of adipocytes induced by IW-1973 was not mediated by changes in HSL, the key enzyme in WAT lipolysis, we explored other mechanisms leading to the reduction in the lipid content such as autophagy. Autophagy is an evolutionary conserved catabolic process by which cellular components are engulfed in an autophagosome and delivered to the lysosome for degradation (Kaur and Debnath, 2015) . Autophagy is emerging as a potential regulator of lipid metabolism and obesity (Liu et al., 2016) , because this process mediates the lipolysis of TAG and reduces the storage of lipids in adipocytes (Singh et al., 2009; López-Vicario et al., 2015; Soussi et al., 2015) . Finally, it is important to mention that in contrast to previous reports by Mitschke et al. (2013) and Hoffmann et al. (2015) , we did not see an increase in WAT browning in IW-1973-treated mice, as UCP1 as well as other thermogenic markers such as CIDEA, PGC-1α and PRDM16 levels remained unchanged in this tissue.
In conclusion, the present study demonstrates at the experimental level that the sGC stimulator IW-1973 attenuates three hallmarks of NASH: hepatic steatosis, inflammation and fibrosis. In addition, the sGC stimulator IW-1973 restored WAT homeostasis, which is an insulin-sensitive tissue that plays a major role in the progression of NASH. Although further studies are needed to clarify the exact mechanisms underlying the beneficial actions of IW-1973 and the modulation of the NO-sGC-cGMP pathway in the liver, our study provides an important evaluation of the properties of sGC stimulators in NASH. Together, our findings contribute to the potential expansion of the therapeutic armamentarium of liver diseases through the modulation of cGMP levels. Future studies are warranted in patients with NASH to fully confirm the clinical relevance of our findings. Selective stimulation of sGC prevents NASH BJP
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